Unique crossover arm study design

Reflects the general inhibitor patient population

The Pro-FEIBA Study was an investigator-initiated, prospective, randomised, crossover arm study conducted at 16 haemophilia treatment centres in Europe and the United States. It compared 6 months of FEIBA prophylaxis with 6 months of on-demand therapy.1

Inclusion criteria

  • Severe haemophilia A and a history of a FVIII inhibitor titre >5 Bethesda Unit (BD)
  • >2 years of age
  • Currently treated with bypassing therapy
  • ≥6 bleeding episodes requiring treatment in the 6 months prior to enrollment

Study Design1

  • Subjects were randomly assigned to study arms with no selection bias related to bleed frequencies1
  • During the 3-month wash-out period prior to crossover, intercurrent bleeding was managed using the on-demand protocol1
  • An independent safety review was also conducted
Learn about the clinical results of the Pro-FEIBA Study >>


  1. 1 Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011; 365:1684-1692.

The results are in

In the Pro-FEIBA study (n=26), FEIBA prophylaxis showed a significant reduction in the frequency of bleeding events in severe haemophilia A patients with FVIII inhibitors Read more


Visit Haemophilia to read the PROOF Study and access to more articles related to managing haemophilia patients with inhibitors. Read more

Sustained activity

FEIBA offers a long dosing interval. Read more

Demonstrated efficacy in prophylaxis

Learn how FEIBA prophylaxis can reduce bleed frequency and preserve joints. Read more

Dosing FEIBA

Learn how to dose FEIBA. Read more